Having demonstrated the utility of the Akt-FRET biosensor mouse in assessing aberrant AKT activity when a tumor suppressor is lost in pancreatic cancer, we went on to additionally show the effect of an activating mutation of PI3K upstream of AKT signaling in the context of immunodeficiency. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.